As reported by Business Week, the Swiss-based pharmaceutical company, Roche, have won backing from the National Institute for Clinical Excellence (NICE) for their advanced lung cancer drug, Tarceva. The drug will be used to treat patients with a certain type of non-small cell lung cancer (NSCLC).
Back in March 2011, Roche’s lung cancer drug was rejected for use by the NHS due to uncertainties with the data in this setting. Following this, Roche was able to submit more analysis to NICE, which were compared to those of AstraZeneca’s Iressa. As a result, NICE have now recommended Tazrceva as a cost effective use of NHS resources.
But the good news doesn’t stop there. The Basel-based pharma company have also agreed to a revised patient access scheme with the Department of Health and have agreed a discount on the drug.